Compare Davita Inc (DVA) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Raymond James Financial, Inc. — how do they compare? Davita Inc trades at $230.51 (market cap $14.92B), while Raymond James Financial, Inc. trades at $166.88 (market cap $32.63B). The key difference: Raymond James Financial, Inc. is far larger — about 2.2× Davita Inc's market cap, and Raymond James Financial, Inc. pays a 1.29% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | RJF | |
|---|---|---|
Market Cap | $14.92B | $32.63B |
Sector | Health | Financials |
52-Week High | $235.71 | $176.43 |
52-Week Low | $103.87 | $140.89 |
Enterprise Value | $27.47B | — |
Dividend Yield | — | 1.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Raymond James Financial (RJF) trades at $166.98, down 0.68% on the day, with a bullish technical outlook and strong fundamental performance. The stock shows consistent earnings beats, with Q1 2026 EPS of $2.83 surpassing expectations of $2.76, and revenue growth from $10.9B in 2022 to $13.84B in 2025. Analyst consensus is positive with a $176.83 price target, and recent news highlights momentum and dividend declarations.
The outlook for RJF remains favorable due to earnings momentum and analyst support, though risks include expense pressures and market volatility. Investment opportunity lies in its valuation below consensus target and dividend growth, but investors should monitor cost management and economic conditions that could impact financial services demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
